Dusigitumab

Dusigitumab
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	ILGF2
Clinical data
ATC code	none;
Identifiers
CAS Number	1204390-13-5;
IUPHAR/BPS	7749;
ChemSpider	none;
KEGG	D10352;
Chemical and physical data
Formula	C6372H9824N1700O2016S54
Molar mass	151 kg/mol

Dusigitumab is a human monoclonal antibody designed for the treatment of cancer. It binds to IGLF2.^[1] It was developed by MedImmune, which was acquired by AstraZeneca, using Xenomouse technology licensed from Abgenix.^[2]

References

↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Dusigitumab, American Medical Association.
↑ http://adisinsight.springer.com/drugs/800030209

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] Statement On A Nonproprietary Name Adopted By The USAN Council - Dusigitumab, American Medical Association.

[2] ttp://adisinsight.springer.com/drugs/800030209